UK clinical trials - updated daily from ClinicalTrials.gov
Understand the key differences between alzheimer's disease and epilepsy clinical trials and research opportunities
The most common cause of dementia, affecting ~600,000 in the UK. Anti-amyloid therapies (lecanemab, donanemab) are driving renewed trial interest.
Affects ~600,000 in the UK. Drug-resistant epilepsy drives significant trial activity in novel AEDs, neuromodulation, and dietary therapies.
Alzheimer's trials are long-duration and focus on cognitive decline slowing. Epilepsy trials are shorter, focusing on seizure frequency reduction.
Search our database of 29,000+ UK clinical trials matched to your condition and profile
Browse Disease PathwaysData sourced from ClinicalTrials.gov. Trial counts are approximate and updated regularly.
TrialConnect is a trading name of Clinical Vendor Compare Limited.
